Page 2 - Nasdaq Path News Today

UiPath (NASDAQ:PATH – Get Rating) and iClick Interactive Asia Group (NASDAQ:ICLK – Get Rating) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Earnings and Valuation This table compares UiPath and […]

Zacks Investment Research cut shares of UiPath (NASDAQ:PATH – Get Rating) from a hold rating to a strong sell rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, “UiPath Inc. offers an end-to-end platform for automation, combining Robotic Process Automation solution for digital business operations. UiPath Inc. is based in […]

UiPath (NASDAQ:PATH – Get Rating) is one of 399 publicly-traded companies in the “Prepackaged software” industry, but how does it weigh in compared to its competitors? We will compare UiPath to related companies based on the strength of its earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown […]

UiPath (NASDAQ:PATH – Get Rating) had its target price reduced by Truist Financial from $75.00 to $55.00 in a report released on Thursday morning, The Fly reports. Truist Financial currently has a buy rating on the healthcare company’s stock. A number of other research firms have also weighed in on PATH. Wells Fargo & Company […]

UiPath (NASDAQ:PATH – Get Rating) had its price objective reduced by Mizuho from $70.00 to $40.00 in a research report sent to investors on Thursday morning, The Fly reports. They currently have a buy rating on the healthcare company’s stock. Other research analysts also recently issued research reports about the company. Berenberg Bank upgraded UiPath […]

UiPath (NASDAQ:PATH – Get Rating) had its price target cut by BMO Capital Markets from $52.00 to $29.00 in a report released on Thursday, The Fly reports. They currently have a market perform rating on the healthcare company’s stock. Several other equities analysts have also recently issued reports on the stock. KeyCorp lowered their target […]

UiPath (NASDAQ:PATH – Get Rating) had its target price cut by Canaccord Genuity Group from $55.00 to $30.00 in a report released on Thursday morning, The Fly reports. A number of other research analysts have also recently commented on the company. Needham & Company LLC reduced their target price on UiPath from $85.00 to $40.00 […]

UiPath (NASDAQ:PATH – Get Rating) had its price objective dropped by stock analysts at Morgan Stanley from $74.00 to $41.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare company’s stock. Morgan Stanley’s price objective points to a potential upside of 84.85% from the stock’s current […]

UiPath (NASDAQ:PATH – Get Rating) had its target price reduced by Needham & Company LLC from $85.00 to $40.00 in a research note released on Thursday morning, The Fly reports. They currently have a buy rating on the healthcare company’s stock. PATH has been the subject of a number of other research reports. Morgan Stanley […]

UiPath (NASDAQ:PATH – Get Rating) had its target price cut by Credit Suisse Group from $75.00 to $57.50 in a research report report published on Thursday morning, The Fly reports. They currently have an outperform rating on the healthcare company’s stock. A number of other analysts have also issued reports on PATH. Morgan Stanley raised […]